Retension Pharmaceuticals Priced 3.75 Million Shares at $12.00 for Its Nasdaq Debut, Upsized From 3.3 Million, With a Going-Concern Paragraph in Its Audit and One Drug in Phase 2b
Retension Pharmaceuticals, Inc. priced its initial public offering of 3,750,000 shares of common stock at $12.00 per share, according to the final prospectus dated Oct. 8, 2026 and filed with the SEC on Oct. 9. The company says its stock is listed on the Nasdaq Capital Market under the symbol "RTSN" and that the underwriters expect to deliver the shares against payment on or about Oct. 13. By our arithmetic, 3,750,000 shares at $12.00 is $45.0 million of gross proceeds; the prospectus itself states estimated net proceeds of approximately $38.9 million after underwriting discounts, commissions and offering expenses.
The deal grew on the way to pricing. The amended registration statement filed Oct. 5 marketed 3,300,000 shares at an anticipated range of "between $11.00 and $13.00 per share," with estimated net proceeds of approximately $33.8 million at the $12.00 midpoint. On Oct. 8, the day the SEC declared the registration effective, Retension filed a Rule 462(b) registration statement "for the sole purpose of registering the sale of an additional $2,415,000.00 of shares," the mechanism issuers use to cover an upsized deal. The underwriters also hold a 30-day option on up to 562,500 additional shares; if exercised in full, the prospectus puts net proceeds at approximately $45.1 million.
Leerink Partners LLC and Guggenheim Securities, LLC are the representatives and bookrunners, with Oppenheimer & Co. Inc. and Titan Partners Securities LLC also named as underwriters, according to the underwriting section, which allocates 1,987,500 shares to Leerink, 1,256,250 to Guggenheim, 318,750 to Oppenheimer and 187,500 to Titan. Directors, officers and holders of substantially all outstanding securities signed 180-day lock-ups that require the consent of Leerink and Guggenheim to waive. Renaissance Capital, in a note dated Oct. 5, had described the then-proposed terms as a $40 million raise that "would command a fully diluted market value of $108 million" at the midpoint.
Retension was incorporated in Delaware on July 26, 2023 and is headquartered in Falls Church, Virginia, the prospectus says. It describes itself as "a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases." It has one product candidate, RTN-001, which it calls "a next-generation, once-daily, oral, small molecule phosphodiesterase-5 ('PDE-5') inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling." The first-generation drugs in that class, as the prospectus notes, include Viagra.
The asset has a long corporate history. According to the prospectus, RTN-001 was conceived at Surface Logix, Inc., where Chief Scientific Officer Paul Sweetnam was CSO; Chief Executive Eric Keller led Surface Logix's 2011 acquisition by Nano Terra, Inc.; the compound was sublicensed to Kadmon, then in 2019 to Redux Therapeutics, LLC, of which Keller and Sweetnam "are each a manager." Retension's rights run through "an exclusive sublicense with Kadmon, a wholly-owned subsidiary of Sanofi (through our sublicense agreement with Redux), as well as upstream licenses," the risk factors say. They add: "All completed clinical trials evaluating RTN-001 to date have been conducted by Surface Logix."
The company's own trial is a Phase 2b dose-ranging study of a modified-release formulation in adults with uncontrolled hypertension who remain on two to five other blood-pressure medications, initiated in October 2025, the prospectus says. The primary endpoint is "the change in peripheral office-seated SBP at week 4 compared to placebo," and the company says "Initial data is expected in the first half of 2027." The prospectus states that RTN-001 "has been administered to 243 participants across nine completed clinical trials, including two Phase 2 pilot trials in hypertension," and that in the largest earlier pilot, Trial 07-08, 40 hypertensive patients received an immediate-release formulation in a crossover design.
Of the net proceeds, the company intends to spend "approximately $18 million to complete the Phase 2b clinical trial of RTN-001 in uHTN," "approximately $10 million to prepare for, support and advance the planned Phase 3 clinical trial of RTN-001 in uHTN," and the remainder on general corporate purposes. It says existing cash plus the offering should fund operations "for at least the next 21 months" from the prospectus date, while acknowledging that "after this offering, we will require substantial capital in order to complete our planned Phase 3 clinical trial."
The financial statements are those of an early-stage company. Cash and cash equivalents were $13.5 million at June 30, 2026, down from $18.9 million at Dec. 31, 2025, the prospectus says. Net losses were $6.3 million for 2025 and $1.9 million for 2024, and $7.5 million for the first six months of 2026 against $1.9 million a year earlier. The accumulated deficit was $15.8 million at June 30. Through that date the company had raised approximately $31.0 million of gross proceeds from convertible preferred stock, including a Series B round in April 2025 that brought in net proceeds of approximately $20.0 million. It has generated no product revenue.
The prospectus carries a going-concern risk factor in unusually direct terms for an IPO: "Our recurring losses from operations and financial condition raise substantial doubt about our ability to continue as a going concern and the report of our independent registered public accounting firm on our financial statements as of and for the fiscal year ended December 31, 2025 includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern." The liquidity discussion says the June 30 cash balance was "not expected to be sufficient to fund our operations for at least twelve months" from the date the interim statements were issued, which is the condition the IPO proceeds are meant to address.
Share counts were reset before pricing. The prospectus discloses "a 1-for-6.21 reverse stock split of our common stock and convertible preferred stock effected on October 2, 2026" and the automatic conversion of all Series A and Series B preferred into common at the closing. On that basis it says 4,581,599 shares were outstanding as of June 30 and that "upon the closing of this offering, we will have a total of 8,331,599 shares of common stock outstanding," before any option exercise (a separate passage, counting from Sept. 30, puts the post-closing figure at approximately 8,332,047). By our arithmetic, 8,331,599 shares at the $12.00 offer price is about $100.0 million of equity value on a basic basis; the company does not state a market capitalisation.
Three directors, Michael Berendt, Donald Olds and Franklin Berger, each reported on Form 4 an award of options over 5,636 shares at a $12.00 exercise price on Oct. 8 under the 2026 Equity Incentive Plan, vesting 25% on the first anniversary of grant and the rest in 12 quarterly increments thereafter. We found no Form 4 reporting an insider purchase in the offering, and the prospectus sections we reviewed do not disclose indications of interest from existing holders.
The company is a "smaller reporting company" and an "emerging growth company," the prospectus says, which permits reduced disclosure. It also says the Phase 2b design is intended to "enable and inform our planned Phase 3 clinical trial," meaning the next value-defining event is the first-half-2027 readout rather than any near-term commercial milestone.
What is next: delivery of the shares on or about Oct. 13 and the underwriters' decision on the 562,500-share option within 30 days of Oct. 8. We have not stated an opening or closing price for the new listing because none appears in the company's filings or the pages we reviewed, and we have not confirmed the first day of trading from a source that states it. Unknown from the documents are whether the option has been exercised and the identity of any institutional buyers in the book.
Sources & further reading
- Retension Pharmaceuticals, Inc., Prospectus (Form 424B4) dated Oct. 8, 2026, filed Oct. 9, 2026
- Retension Pharmaceuticals, Inc., Amendment No. 1 to Form S-1 (price range $11.00-$13.00, 3,300,000 shares), filed Oct. 5, 2026
- Retension Pharmaceuticals, Inc., Form S-1MEF (Rule 462(b), additional $2,415,000 of shares), filed Oct. 8, 2026
- SEC EDGAR, Retension Pharmaceuticals filing index (Form 8-A12B Oct. 8, EFFECT Oct. 8, Forms 3 and 4)
- Renaissance Capital, 'Hypertension drug developer Retension Pharmaceuticals sets terms for $40 million IPO', Oct. 5, 2026
- Retension Pharmaceuticals, Inc., Form 4 for director Michael J. Berendt, filed Oct. 8, 2026